2011 Annual Meeting of the Safety Pharmacology Society: an overview

Bibliography

• Cavero I, Crumb W. Safety Pharmacology Society: 5th Annual Meeting, 27 – 29 September, 2005, Mannheim, Germany. Expert Opin Drug Saf 2006;5:181-5
   PubMedGoogle Scholar
• Cavero I. Safety Pharmacology Society: 6th Annual Meeting 26-28 September, 2006, San Diego, USA. Expert Opin Drug Saf 2007;6:87-92
   Google Scholar
• Cavero I. Safety Pharmacology Society: 7th Annual Meeting 19-20 September, 2007, Edinburgh, UK. Expert Opin Drug Saf 2008;7:91-100
   PubMed Web of Science ®Google Scholar
• Cavero I. Safety Pharmacology Society: 8th Annual Meeting 22-25 September, 2008, Madison, USA. Expert Opin Drug Saf 2009;8:1-11
   PubMed Web of Science ®Google Scholar
• Cavero I. Safety Pharmacology Society: 9th Annual Meeting 15-18 September, 2009, Strasbourg, France. Expert Opin Drug Saf 2010;9:365-78
   PubMedGoogle Scholar
• Cavero I. 10th annual meeting of the Safety Pharmacology Society: an overview. Expert Opin Drug Saf 2011;10:319-33
   PubMedGoogle Scholar
• Rosner MH, Okusa MD. Drug-associated acute kidney injury in the intensive care unit. In: De Broe ME, Porter GA, editor. Clinical Nephrotoxins: renal injury fromdrugs and chemicals. Kluwer Springer: 2008. p. 223-50
   Google Scholar
• Muller PY, Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 2009;5:1023-38
   PubMed Web of Science ®Google Scholar
• Wieser M, Stadler G, Jennings P, hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol 2008;295:F1365-75
   PubMed Web of Science ®Google Scholar
• Limonciel A, Aschauer L, Wilmes A, Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes. Toxicol In Vitro 2011;25:1855-62
   PubMed Web of Science ®Google Scholar
• Wilmes A, Crean D, Aydin S, Identification and dissection of the Nrf2 mediated oxidative stress pathway in human renal proximal tubule toxicity. Toxicol In Vitro 2011;25:613-22
   PubMed Web of Science ®Google Scholar
• Sarazan RD, Schweitz KT. Standing on the shoulders of giants: Dean Franklin and his remarkable contributions to physiological measurements in animals. Adv Physiol Educ 2009;33:144-56
   PubMed Web of Science ®Google Scholar
• Sarazan RD, Starke WA, Krause GF, Cardiovascular effects of detomidine a new alpha2-agonist, in conscious ponies. J Vet Pharmacol Ther 1989;12:378-88
   PubMed Web of Science ®Google Scholar
• ICH Harmonised Tripartite Guideline. Safety pharmacology studies for human pharmaceuticals S7A. 2000. Available from: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf
   Google Scholar
• ICH Harmonised Tripartite Guideline. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. May 2005. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf
   Google Scholar
• Cavero I, Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin Drug Saf 2005;4:509-30
   PubMedGoogle Scholar
• Chen MH. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Curr Cardiol Rep 2009;11:167-74
   PubMedGoogle Scholar
• Pettit SD, Berridge B, Sarazan RD. A call for more integrated cardiovascular safety assessment. J Pharmacol Toxicol Methods 2010;61:1-2
   PubMed Web of Science ®Google Scholar
• Sarazan RD, Mittelstadt S, Guth B, Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities. Int J Toxicol 2011;30:272-86
   PubMed Web of Science ®Google Scholar
• Trepakova ES, Koerner J, Pettit SD, Valentin JP; HESI Pro-arrhythmia Committee. A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J Pharmacol Toxicol Methods 2009;60:45-50
   PubMedGoogle Scholar
• Liu T, Brown BS, Wu Y, Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006;3:948-56
   PubMed Web of Science ®Google Scholar
• Liu T, Brown BS, Wu Y, Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006;3:948-56
   PubMed Web of Science ®Google Scholar
• Lu HR, Rohrbacher J, Vlaminckx E, Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the ‘bad’ sodium current blockers. Br J Pharmacol 2010;160:60-76
   PubMed Web of Science ®Google Scholar
• Towart R, Linders JT, Hermans AN, Blockade of the IKs potassium channel: an overlooked cardiovascular liability in drug safety screening? J Pharmacol Toxicol Methods 2009;60:1-10
   PubMedGoogle Scholar
• van der Linde HJ, Van Deuren B, Somers Y, The Electro-Mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias. Br J Pharmacol 2010;161:1444-54
   PubMed Web of Science ®Google Scholar
• Available from: https://gostardb.com/gostar/
   Google Scholar
• Ingber DE. The Wyss Institute at Harvard University. IEEE Pulse 2011;2:43-6
   PubMed Web of Science ®Google Scholar
• Huh D, Hamilton G, Ingber DE. From three-dimensional cell culture to organs-on-chips. Trends Cell Biol 2011;21:745-54
   PubMed Web of Science ®Google Scholar
• MacDonald JS, Robertson RT. Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol Sci 2009;110:40-6
   PubMed Web of Science ®Google Scholar
• Braam SR, Tertoolen L, van de Stolpe A, Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 2010;4:107-16
   PubMed Web of Science ®Google Scholar
• Guo L, Abrams RM, Babiarz JE, Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 2011;123:281-9
   PubMed Web of Science ®Google Scholar
• Halbach M, Egert U, Hescheler J, Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol Biochem 2003;13:271-84
   Google Scholar
• Huang S, Wiszniewski L, In vitro organ culture models of asthma. Drug Discovery Today 2009;6(4):137-44
   Google Scholar
• Huang S, Wiszniewski L, Constant S, The use of in vitro 3D cell models in drug development for respiratory diseases. In Tech December 2011. Available from: www.intechopen.com/source/pdfs/25227/InTech-The_use_of_in_vitro_3d_cell_models_in_drug_development_for_respiratory_diseases.pdf
   Google Scholar
• Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 2011;8:1281-90
   PubMed Web of Science ®Google Scholar
• Valentin JP, Bialecki R, Ewart L, A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 2009;60:152-8
   PubMedGoogle Scholar
• Cavero I. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations. Expert Opin Drug Saf 2009;8:627-47
   PubMed Web of Science ®Google Scholar
• Guidance for industry qualification process for drug development tools. October 2010. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf
   Google Scholar
• Cavero I. Promises and partnership: FDA's critical path initiative and its intersection with pharmacology: an ASPET 2011 annual meeting symposium. Expert Opin Drug Saf 2011;10:827-37
   Web of Science ®Google Scholar
• Bass AS, Vargas HM, Valentin JP, Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society. J Pharmacol Toxicol Methods 2011;64:7-15
   PubMed Web of Science ®Google Scholar
• Cavero I. Cardiovascular system assessment best practices: a safety pharmacology society meeting. Expert Opin Drug Saf 2010;9:855-66
   Google Scholar
• Leishman DJ, Beck TW, Dybdal N, Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the safety pharmacology society. J Pharmacol Toxicol Methods 2011; In press
   PubMed Web of Science ®Google Scholar
• Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 2008;154:1528-37
   PubMed Web of Science ®Google Scholar